logobeta
본 영문본은 리걸엔진의 AI 번역 엔진으로 번역되었습니다. 수정이 필요한 부분이 있는 경우 피드백 부탁드립니다.
텍스트 조절
arrow
arrow
(영문) 서울고등법원 2017.02.23 2016누64977
유족급여및장의비부지급처분취소
Text

1. Revocation of a judgment of the first instance;

2. The plaintiffs' claims are dismissed.

3. The costs of the lawsuit are assessed against the Plaintiffs.

Reasons

1. This court's explanation concerning this part of the reasons for the disposition is the same as the corresponding part of the judgment of the court of first instance, and thus, citing it in accordance with Article 8(2) of the Administrative Litigation Act and the main sentence of Article 420 of the

2. Whether the rejection disposition of this case is legitimate

A. 1) The Deceased’s past work records (A) performed research on medical devices, such as a key for pregnancy diagnosis, from March 2002 to April 2005, from July 2006 to October 2009, and from July 2006 to October 2009.

B) The content of the work (1) the Deceased worked on the five-day basis per week, and the working hours are from 9:00 to 18:00 to 13:00. (2) The diagnosis production technology team belonging to the Deceased is to develop medical devices, such as blood agents, diagnostic cards, etc., and mass products (Pilot; hereinafter “Pilot”).

(3) The deceased performed the work of reviewing and verifying the performance of the system, building the mass production system, and improving the production process within the diagnosis and production technology team, including ① the mass production transfer of developed products, ② the improvement of production process, ③ the formulation and implementation of the production plan, ④ the verification and confirmation work, ⑤ the review and revision of the work standard and the manufacturing instruction.

(ii)for the purpose of screening the heart disease, such as the hardiac Triple (e.g., heart color);

(ii) BNP (goods to detect heart diseases, such as hearts, etc.);

(2) At the end of June 2013, TSH and NP were in charge of the mass production transfer of Vitamin D and Tosterone products. Among them, ICC transferred the mass production work to the aim of June 2013, 2013. (2) At the end of June 2013, Avidin (the treatment reagents).

(3), (4), and (5) both work have been conducted in parallel. (4) The production process improvement work, such as optimalization and the improvement of the sales process, and (4) the work has also been conducted.

arrow